
Merck Serono gains head of global clinical development
pharmafile | April 17, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alise Reicin, Merck, Merck Serono
Merck Serono, the biopharma business of Merck, has appointed Dr Alise Reicin as senior vice president and head of its global clinical development.
Reicin has served as a vice president in various capacities across R&D at Merck for the last 10 years, and was previously VP for project and pipeline leadership within its oncology franchise at the US company.
Reicin will report to Luciano Rossetti, head of global R&D, and will join Merck Serono on 11 May based in Massachusetts in the US. In her new role she is to oversee the firm’s clinical development organisation across various therapy areas, leading its portfolio.
“We are honoured to have Alise join Merck Serono,” says Luciano Rossetti head of R&D. “Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organisation. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating model.”
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






